Stimulated rat peritoneal neutrophils release a platelet inhibitory factor with the pharmacological properties of NO. This release is inhibited by N0-monomethyl-L-arginine and L-canavanine, indicating that it occurs through a mechanism similar to that in vascular endothelial cells and macrophages. As the degree of stimulation increases, the factor released is progressively inactivated by concomitant release of superoxide anions.
INTRODUCTION
Neutrophils (PMN) release a factor, with the pharmacological profile of NO, which relaxes vascular smooth muscle [1] and inhibits platelet aggregation [2] . When stimulated with a variety of substances, such as fMet-Leu-Phe (FMLP), PMN also release other factors, including superoxide anion (02-; for a review, see [3] ) which inactivates NO [4] .
Vascular endothelial cells [5] and macrophages [6] synthesize NO from the terminal guanidino nitrogen atom(s) of the amino acid L-arginine. This synthesis of NO is inhibited by NG-monomethyl-L-arginine (L-NMMA), which also inhibits both endotheliumdependent vasodilatation in vitro and in vivo and some of the cytotoxic actions of macrophages (for a review see [7] ).
We have now investigated the release from rat PMN of a platelet inhibitory factor with the properties of NO, its interaction with 02-and the biochemical mechanism leading to its synthesis.
MATERIALS AND METHODS Preparation of platelets and PMN
Human platelets, washed with prostacyclin, were prepared from citrated blood as described previously [8] and were resuspended in Tyrode's solution at a final concentration of 2 x 108 platelets * ml-'.
Peritoneal PMN were elicited with oyster glycogen and harvested from male Wistar rats (200-250 g body wt.) as described previously [9] . The fMet-Leu-Phe; 02-, superoxide anion; SOD, superoxide dismutase;
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The anti-aggregating activity of 3 x 105 PMN in the presence of SOD (82 + 9 %) was reduced to 71 + 7, 59 + 6 and 39+8 % by 0.1, 0.3 and 1 mM-L-canavanine respectively (n = 3). The effect of L-canavanine (1 mM) was similarly dependent on the time of preincubation, being maximal at 50 min (n = 3) and was abolished by Larginine (1 mM; n = 3). None of these concentrations of L-canavanine affected PMN viability (n = 3). Effect of FMLP and LTB4 The inhibition of platelet aggregation by 3 x 105 PMN was significantly enhanced by low concentrations of FMLP, added to the platelets 1 min before the addition of PMN. Higher concentrations of FMLP, which did not affect platelet aggregation directly, reversed this effect and reduced the inhibition to below control levels (Fig. 2). The release of 02 induced by higher concentrations of FMLP was detectable using the cytochrome c assay (Fig. 2) . The enhanced inhibition of platelet aggregation by 10-10 M-FMLP-stimulated PMN was reduced by 90 + 8 % by haemoglobin (200 nM; n = 3) and by 88 + 60 by L-NMMA (100,UM; n = 3).
The effect of FMLP in the presence of SOD was investigated using 1 x 105 PMN with 60 units of SOD* ml-l, which were as effective as 3 x 105 PMN alone in inhibiting platelet aggregation. Under these conditions, the enhancement of anti-aggregating activity of FMLP was significantly potentiated, and the reversal of this effect to below control levels by higher concentrations of FMLP was not observed (Fig. 2) .
The inhibition of platelet aggregation by PMN was also significantly enhanced by LTB4 (106 M; Fig. 3 ). The enhancement by LTB4 of the anti-aggregating activity was potentiated by SOD (Fig. 3) . The release of 02-2 detected by reduction of cytochrome c, was only significant at the highest concentration of LTB4 (Fig. 3) .
L-Arginine (300 /uM) alone did not affect the antiaggregating activity of PMN. It did, however, potentiate significantly (from 69+5 to 93+4 %) the enhancement of anti-aggregating activity of 
DISCUSSION
Rat peritoneal PMN inhibited platelet aggregation in a cell-concentration-dependent manner. This anti-aggregating activity was potentiated by SOD and by a selective cyclic GMP phosphodiesterase inhibitor, M&B 22948, and was inhibited by haemoglobin and by treatment of the cells with glutaraldehyde. This indicates that viable PMN release NO, which inhibits platelet aggregation via elevation of cyclic GMP- [13] .
The anti-aggregating activity of PMN was significantly reduced by L-NMMA, but"not by D-NMMA, and this effect was reversed by L-arginine. This shows that NO is formed from L-arginine in these cells and that this occurs via an enzymic mechanism similar to that in the vascular endothelium [5, 15] and the macrophage [6, 16] . The substrate and inhibitor profile for NO synthesis in PMN is similar to that in macrophages [6] , but differs somewhat from that in endothelial cells [5] and endothelial-cell homogenates [15] , since L-canavanine is an inhibitor in macrophages [17] hancement, but also reduced the anti-aggregating activity to below the control level. Since NO is inactivated by 02- [4] and these concentrations of FMLP induce its release from PMN, this inhibition is probably due to inactivation of NO by 02-, for SOD prevented this effect.
LTB4 also enhanced the anti-aggregating activity of PMN. However, a reversal of this effect was not observed with high concentrations of LTB4, and this agonist only released small amounts of 02-at these concentrations.
This indicates not only that LTB4, unlike FMLP, is a weak stimulator of NO generation, but also that it does not release sufficient 02-to overcome the anti-aggregating effect of NO. Interestingly, L-arginine, like SOD, potentiated the anti-aggregating activity induced by low concentrations of FMLP and inhibited the reversal of this action observed with high concentrations of this agonist. This shows that the same biological effect can be achieved either by scavenging 02-(with SOD) or by increasing the levels of NO (with L-arginine).
The [18] , require elucidation. The L-arginine/NO biosynthetic pathway is widely distributed and underlies a variety of functions which range from vasodilatation in the vascular system to cytotoxicity in the macrophage [7] . Since it is likely that this is a system of isoenzymes, inhibitors with selectivity towards one or another cell type will help clarify the role of NO in the different cells in vivo as well as the origin of the excess NO3-excreted by the whole animal [19] . Unlike L-NMMA, which is a general inhibitor of the pathway, L-canavanine shows selectivity towards the enzyme in the macrophage [17] and the PMN, land is therefore suitable for investigating the role of NO derived from phagocytes.
